ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL CANCER INSTITUTE

A transdisciplinary approach for dissecting stem cell states in prostate cancer

Completed
Institution
COLUMBIA UNIVERSITY HEALTH SCIENCES, NY
Principal investigator
Raul Rabadan
Funding
$632K
Duration
2021–2026
Open portfolio

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY/ABSTRACT Understanding the molecular mechanisms that drive prostate cancer progression has profound significance for defining the biology of lethal prostate cancer. The cancer stem cell model proposes that cells within a tumor are organized in a hierarchical lineage relationship and display different tumorigenic potential. This model has important translational implications since it suggests that effective therapeutics should target cancer stem cells that sustain tumor malignancy. However, despite intensive investigation, long-standing questions about the existence and properties of prostate cancer stem cells remain unresolved. To identify, characterize, and therapeutically target this population, we will combine the expertise of cancer stem cell researchers with computational/mathematical approaches. Leveraging techniques from theoretical physics (Random Matrix Theory) and algebraic topology (Topological Data Analysis), we will provide a statistical framework to dissect a molecular signature (termed CasPro) implicated in progenitor activity in prostate tumors. We will experimentally validate our findings by investigating CasPro-high cells in genetically-engineered mouse models of prostate cancer and analyzing their functional properties in assays of stem cell activities. These findings will then be further validated in studies of human prostate tumor samples, particularly from patients with treatment-resistant castration-resistant prostate cancer (CRPC). In the longer-term, we anticipate that our studies of key regulators of the stem cell signature as well as the epigenomic landscape of CasPro-high cells will identify novel targets for therapy, and lead to novel candidate drugs for these targets. Further development of candidate drugs might result in inhibition of cancer stem cell activity, thereby providing potential treatments for CRPC.

Research team

  • Raul RabadanPI
  • Michael M. ShenPI

LOADING MOONBASE SCORE

NATIONAL CANCER INSTITUTEU01ZCA1-TCRB-Q(M1)cancerprostateprostate cancercancer stemcrpcstem cellstemsignature

Questions for COLUMBIA UNIVERSITY HEALTH SCIENCES

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.